What did @mariaquoz actually say?
This is a tricky one to fact-check. The transcript provided for this video appears to be garbled, likely the result of an auto-transcription error on a Spanish-language video. The caption tells us more than the transcript does: @mariaquoz says she was diagnosed with type 2 diabetes, is using Ozempic (semaglutide), and has experienced side effects she wanted to share with other women. The hashtags include caidadecabello and perdidadecabello, both meaning hair loss, which strongly suggests that was at least one side effect she discussed. Her framing is careful and worth noting: she explicitly says she is not encouraging anyone to stop the medication or fear it. That kind of disclaimer is more responsible than what you usually see in GLP-1 content on TikTok.
Does the science back up hair loss on semaglutide?
Yes, and more than the drug labels initially suggested. Hair loss, or telogen effluvium, is a real and documented side effect in people taking GLP-1 receptor agonists. The best evidence suggests it is mostly tied to rapid caloric restriction and weight loss rather than the drug molecule itself, but the distinction matters less to the person watching clumps of hair come out in the shower.
A 2023 analysis of FDA Adverse Event Reporting System (FAERS) data found that alopecia reports were significantly elevated in semaglutide users compared to baseline expectations (Bourgeois et al., 2023, JAMA Dermatology). Separately, the SUSTAIN and STEP trial programs did not list hair loss as a primary endpoint, meaning it was likely underreported in the formal clinical trial data. Real-world post-market data is filling that gap now. The American Academy of Dermatology has acknowledged telogen effluvium as a recognized complication of significant weight loss, regardless of how that weight loss is achieved.
What did she get wrong, or right?
Based on what we can infer, she got the core experience right. Hair loss on Ozempic is real, under-discussed in clinical settings, and disproportionately affects women, who are also more likely to notice and report it. Her decision to frame this as a personal share rather than a medical recommendation is the correct approach, and it is the kind of disclosure regulators actually want creators to make.
What we cannot confirm is whether she made any mechanistic claims about why hair loss happens or whether she attributed it entirely to the drug rather than the weight loss process. That distinction matters clinically. Patients who understand the mechanism are better positioned to talk to their prescriber about nutritional support, protein intake, and whether dose titration makes sense. If she skipped that nuance, it is a gap, not a falsehood.
What should you actually know?
If you are on a GLP-1 receptor agonist and noticing hair thinning, here is what the evidence actually supports:
- Telogen effluvium typically begins two to four months after a significant physiological stressor, which can include rapid weight loss. It is usually temporary.
- Protein intake is consistently flagged in clinical nutrition literature as a modifiable factor. Studies suggest patients on GLP-1 medications often undereat protein due to appetite suppression (Wilding et al., 2021, NEJM).
- Hair loss does not mean the medication is harming you. It may mean your body needs nutritional support alongside the medication.
- Talk to your prescriber before adjusting your dose or stopping the medication based on this side effect alone. The cardiovascular and glycemic benefits of semaglutide in type 2 diabetes are substantial and documented across major trials.
The bigger picture on patient-created GLP-1 content
@mariaquoz is doing something most pharmaceutical companies do not bother to do: telling real women what to expect before they are already three months in and panicking. The clinical trial consent forms mention hair loss in fine print. TikTok is where people actually find out it can happen. That is a problem with how drug information reaches patients, not a problem with creators like her. What would make this content better is pairing the personal experience with a prompt to discuss it with a prescriber, which, based on her caption framing, she may have done.